DOI: 10.1158/1535-7163.mct-05-0081. Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL

Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL

10.1158/1535-7163.mct-05-0081

Crossref journal-article

American Association for Cancer Research (AACR)

Molecular Cancer Therapeutics (1086)

Abstract

Abstract Organ preservation protocols in head and neck squamous cell carcinoma (HNSCC) are limited by tumors that fail to respond. We observed that larynx preservation and response to chemotherapy is significantly associated with p53 overexpression, and that most HNSCC cell lines with mutant p53 are more sensitive to cisplatin than those with wild-type p53. To investigate cisplatin resistance, we studied two HNSCC cell lines, UM-SCC-5 and UM-SCC-10B, and two resistant sublines developed by cultivation in gradually increasing concentrations of cisplatin. The cisplatin-selected cell lines, UM-SCC-5PT and UM-SCC-10BPT, are 8 and 1.5 times more resistant to cisplatin than the respective parental cell lines, respectively. The parental lines overexpress p53 and contain p53 mutations but the cisplatin-resistant cell lines do not, indicating that cells containing mutant p53 were eliminated during selection. Bcl-xL expression increased in the cisplatin-resistant lines relative to the parental lines, whereas Bcl-2 expression was high in the parental lines and decreased in the cisplatin-resistant lines. Thus, cisplatin selected for wild-type p53 and high Bcl-xL expression in these cells. We tested a small-molecule BH3 mimetic, (−)-gossypol, which binds to the BH3 domain of Bcl-2 and Bcl-xL, for activity against the parental and cisplatin-resistant cell lines. At physiologically attainable levels, (−)-gossypol induces apoptosis in 70% to 80% of the cisplatin-resistant cells but only in 25% to 40% of the parental cells. Thus, cisplatin-resistant cells seem to depend on wild-type p53 and Bcl-xL for survival and BH3 mimetic agents, such as (−)-gossypol, may be useful adjuncts to overcome cisplatin resistance in HNSCC.

Bibliography

Bauer, J. A., Trask, D. K., Kumar, B., Los, G., Castro, J., Shin-Jung Lee, J., Chen, J., Wang, S., Bradford, C. R., & Carey, T. E. (2005). Reversal of cisplatin resistance with a BH3 mimetic, (â)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Molecular Cancer Therapeutics, 4(7), 1096â1104.

Authors 10

Joshua A. Bauer (first)
Douglas K. Trask (additional)
Bhavna Kumar (additional)
Gerrit Los (additional)
Jason Castro (additional)
Julia Shin-Jung Lee (additional)
Jianyong Chen (additional)
Shaomeng Wang (additional)
Carol R. Bradford (additional)
Thomas E. Carey (additional)

References 47 Referenced 102

Dates

Type	When
Created	19 years, 11 months ago (Sept. 22, 2005, 4:51 p.m.)
Deposited	3 years, 2 months ago (June 8, 2022, 5:03 a.m.)
Indexed	1 month, 1 week ago (July 24, 2025, 8:20 a.m.)
Issued	20 years, 2 months ago (July 1, 2005)
Published	20 years, 2 months ago (July 1, 2005)
Published Online	20 years, 1 month ago (July 14, 2005)
Published Print	20 years, 2 months ago (July 1, 2005)

Funders 0

None

BibTeX

@article{Bauer_2005, title={Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL}, volume={4}, ISSN={1538-8514}, url={http://dx.doi.org/10.1158/1535-7163.mct-05-0081}, DOI={10.1158/1535-7163.mct-05-0081}, number={7}, journal={Molecular Cancer Therapeutics}, publisher={American Association for Cancer Research (AACR)}, author={Bauer, Joshua A. and Trask, Douglas K. and Kumar, Bhavna and Los, Gerrit and Castro, Jason and Shin-Jung Lee, Julia and Chen, Jianyong and Wang, Shaomeng and Bradford, Carol R. and Carey, Thomas E.}, year={2005}, month=jul, pages={1096–1104} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        7,
        24
      ]
    ],
    "date-time": "2025-07-24T12:20:53Z",
    "timestamp": 1753359653485
  },
  "reference-count": 47,
  "publisher": "American Association for Cancer Research (AACR)",
  "issue": "7",
  "content-domain": {
    "domain": [
      "aacrjournals.org"
    ],
    "crossmark-restriction": true
  },
  "published-print": {
    "date-parts": [
      [
        2005,
        7,
        1
      ]
    ]
  },
  "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Organ preservation protocols in head and neck squamous cell carcinoma (HNSCC) are limited by tumors that fail to respond. We observed that larynx preservation and response to chemotherapy is significantly associated with p53 overexpression, and that most HNSCC cell lines with mutant p53 are more sensitive to cisplatin than those with wild-type p53. To investigate cisplatin resistance, we studied two HNSCC cell lines, UM-SCC-5 and UM-SCC-10B, and two resistant sublines developed by cultivation in gradually increasing concentrations of cisplatin. The cisplatin-selected cell lines, UM-SCC-5PT and UM-SCC-10BPT, are 8 and 1.5 times more resistant to cisplatin than the respective parental cell lines, respectively. The parental lines overexpress p53 and contain p53 mutations but the cisplatin-resistant cell lines do not, indicating that cells containing mutant p53 were eliminated during selection. Bcl-xL expression increased in the cisplatin-resistant lines relative to the parental lines, whereas Bcl-2 expression was high in the parental lines and decreased in the cisplatin-resistant lines. Thus, cisplatin selected for wild-type p53 and high Bcl-xL expression in these cells. We tested a small-molecule BH3 mimetic, (\u2212)-gossypol, which binds to the BH3 domain of Bcl-2 and Bcl-xL, for activity against the parental and cisplatin-resistant cell lines. At physiologically attainable levels, (\u2212)-gossypol induces apoptosis in 70% to 80% of the cisplatin-resistant cells but only in 25% to 40% of the parental cells. Thus, cisplatin-resistant cells seem to depend on wild-type p53 and Bcl-xL for survival and BH3 mimetic agents, such as (\u2212)-gossypol, may be useful adjuncts to overcome cisplatin resistance in HNSCC.</jats:p>",
  "DOI": "10.1158/1535-7163.mct-05-0081",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2005,
        9,
        22
      ]
    ],
    "date-time": "2005-09-22T20:51:01Z",
    "timestamp": 1127422261000
  },
  "page": "1096-1104",
  "update-policy": "http://dx.doi.org/10.1158/crossmark_policy",
  "source": "Crossref",
  "is-referenced-by-count": 102,
  "title": "Reversal of cisplatin resistance with a BH3 mimetic, (\u2212)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL",
  "prefix": "10.1158",
  "volume": "4",
  "author": [
    {
      "given": "Joshua A.",
      "family": "Bauer",
      "sequence": "first",
      "affiliation": [
        {
          "name": "1Pharmacology, Departments of"
        }
      ]
    },
    {
      "given": "Douglas K.",
      "family": "Trask",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "2Otolaryngology-Head and Neck Surgery, and"
        }
      ]
    },
    {
      "given": "Bhavna",
      "family": "Kumar",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "2Otolaryngology-Head and Neck Surgery, and"
        }
      ]
    },
    {
      "given": "Gerrit",
      "family": "Los",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "6Pfizer Global Research and Development, La Jolla, California"
        }
      ]
    },
    {
      "given": "Jason",
      "family": "Castro",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "2Otolaryngology-Head and Neck Surgery, and"
        }
      ]
    },
    {
      "given": "Julia",
      "family": "Shin-Jung Lee",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "4Biostatistics Unit; and"
        },
        {
          "name": "5University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan; and"
        }
      ]
    },
    {
      "given": "Jianyong",
      "family": "Chen",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "3Internal Medicine and Medicinal Chemistry;"
        }
      ]
    },
    {
      "given": "Shaomeng",
      "family": "Wang",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "3Internal Medicine and Medicinal Chemistry;"
        },
        {
          "name": "5University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan; and"
        }
      ]
    },
    {
      "given": "Carol R.",
      "family": "Bradford",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "2Otolaryngology-Head and Neck Surgery, and"
        },
        {
          "name": "5University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan; and"
        }
      ]
    },
    {
      "given": "Thomas E.",
      "family": "Carey",
      "sequence": "additional",
      "affiliation": [
        {
          "name": "1Pharmacology, Departments of"
        },
        {
          "name": "2Otolaryngology-Head and Neck Surgery, and"
        },
        {
          "name": "5University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan; and"
        }
      ]
    }
  ],
  "member": "1086",
  "published-online": {
    "date-parts": [
      [
        2005,
        7,
        14
      ]
    ]
  },
  "reference": [
    {
      "key": "2022060808370904900_BIB1",
      "doi-asserted-by": "crossref",
      "unstructured": "Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci\u20081995;20:435\u20139.",
      "DOI": "10.1016/S0968-0004(00)89095-7"
    },
    {
      "key": "2022060808370904900_BIB2",
      "doi-asserted-by": "crossref",
      "unstructured": "Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev\u20081999;99:2451\u201366.",
      "DOI": "10.1021/cr980420v"
    },
    {
      "key": "2022060808370904900_BIB3",
      "doi-asserted-by": "crossref",
      "unstructured": "Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med\u20081993;328:184\u201394.",
      "DOI": "10.1056/NEJM199301213280306"
    },
    {
      "key": "2022060808370904900_BIB4",
      "doi-asserted-by": "crossref",
      "unstructured": "Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med\u20081991;324:1685\u201390.",
      "DOI": "10.1056/NEJM199106133242402"
    },
    {
      "key": "2022060808370904900_BIB5",
      "doi-asserted-by": "crossref",
      "unstructured": "el-Deiry WS. p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol\u20081998;227:121\u201337.",
      "DOI": "10.1007/978-3-642-71941-7_6"
    },
    {
      "key": "2022060808370904900_BIB6",
      "doi-asserted-by": "crossref",
      "unstructured": "Levine AJ. p53, the cellular gatekeeper for growth and division. Cell\u20081997;88:323\u201331.",
      "DOI": "10.1016/S0092-8674(00)81871-1"
    },
    {
      "key": "2022060808370904900_BIB7",
      "doi-asserted-by": "crossref",
      "unstructured": "Moll UM, Schramm LM. p53\u2014an acrobat in tumorigenesis. Crit Rev Oral Biol Med\u20081998;9:23\u201337.",
      "DOI": "10.1177/10454411980090010101"
    },
    {
      "key": "2022060808370904900_BIB8",
      "doi-asserted-by": "crossref",
      "unstructured": "Wynford-Thomas D. p53: guardian of cellular senescence. J Pathol\u20081996;180:118\u201321.",
      "DOI": "10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I"
    },
    {
      "key": "2022060808370904900_BIB9",
      "doi-asserted-by": "crossref",
      "unstructured": "Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg\u20081995;113:408\u201312.",
      "DOI": "10.1016/S0194-5998(95)70077-3"
    },
    {
      "key": "2022060808370904900_BIB10",
      "doi-asserted-by": "crossref",
      "unstructured": "Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck\u20082003;25:654\u201361.",
      "DOI": "10.1002/hed.10274"
    },
    {
      "key": "2022060808370904900_BIB11",
      "doi-asserted-by": "crossref",
      "unstructured": "Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science\u20081997;275:343\u20139.",
      "DOI": "10.1126/science.275.5298.343"
    },
    {
      "key": "2022060808370904900_BIB12",
      "doi-asserted-by": "crossref",
      "unstructured": "Kovach JS, Hartmann A, Blaszyk H, et al. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A\u20081996;93:1093\u20136.",
      "DOI": "10.1073/pnas.93.3.1093"
    },
    {
      "key": "2022060808370904900_BIB13",
      "doi-asserted-by": "crossref",
      "unstructured": "Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood\u20081997;89:601\u20139.",
      "DOI": "10.1182/blood.V89.2.601"
    },
    {
      "key": "2022060808370904900_BIB14",
      "doi-asserted-by": "crossref",
      "unstructured": "Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood\u20081994;84:3148\u201357.",
      "DOI": "10.1182/blood.V84.9.3148.bloodjournal8493148"
    },
    {
      "key": "2022060808370904900_BIB15",
      "doi-asserted-by": "crossref",
      "unstructured": "Bradford CR, Zhu S, Poore J, et al. p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg\u20081997;123:605\u20139.",
      "DOI": "10.1001/archotol.1997.01900060047008"
    },
    {
      "key": "2022060808370904900_BIB16",
      "doi-asserted-by": "crossref",
      "unstructured": "Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature\u20081997;385:123\u20135.",
      "DOI": "10.1038/385123b0"
    },
    {
      "key": "2022060808370904900_BIB17",
      "unstructured": "Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res\u20081996;56:892\u20138."
    },
    {
      "key": "2022060808370904900_BIB18",
      "unstructured": "Fan S, Smith ML, Rivet DJ II, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res\u20081995;55:1649\u201354."
    },
    {
      "key": "2022060808370904900_BIB19",
      "doi-asserted-by": "crossref",
      "unstructured": "Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol Life Sci\u20081999;55:64\u201375.",
      "DOI": "10.1007/s000180050270"
    },
    {
      "key": "2022060808370904900_BIB20",
      "doi-asserted-by": "crossref",
      "unstructured": "Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol\u20081994;5 Suppl 1:61\u20135.",
      "DOI": "10.1093/annonc/5.suppl_1.S61"
    },
    {
      "key": "2022060808370904900_BIB21",
      "unstructured": "Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene\u20081995;11:1389\u201394."
    },
    {
      "key": "2022060808370904900_BIB22",
      "doi-asserted-by": "crossref",
      "unstructured": "Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology\u20082001;34:55\u201361.",
      "DOI": "10.1053/jhep.2001.25387"
    },
    {
      "key": "2022060808370904900_BIB23",
      "doi-asserted-by": "crossref",
      "unstructured": "Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope\u20082002;112:638\u201344.",
      "DOI": "10.1097/00005537-200204000-00009"
    },
    {
      "key": "2022060808370904900_BIB24",
      "doi-asserted-by": "crossref",
      "unstructured": "Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (\u2212)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res\u20082004;10:7757\u201363.",
      "DOI": "10.1158/1078-0432.CCR-04-0551"
    },
    {
      "key": "2022060808370904900_BIB25",
      "doi-asserted-by": "crossref",
      "unstructured": "Carey TE. Head and neck tumor cell lines. In: Hay R, Gazdar A, Park J-G, editors. Atlas of human tumor cell lines. San Diego (CA): Academic Press, Inc.; 1994. p. 79\u2013120.",
      "DOI": "10.1016/B978-0-12-333530-2.50007-1"
    },
    {
      "key": "2022060808370904900_BIB26",
      "doi-asserted-by": "crossref",
      "unstructured": "Nakata B, Albright KD, Barton RM, Howell SB, Los G. Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol\u20081995;35:511\u20138.",
      "DOI": "10.1007/BF00686837"
    },
    {
      "key": "2022060808370904900_BIB27",
      "doi-asserted-by": "crossref",
      "unstructured": "Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev\u20082003;103:645\u201362.",
      "DOI": "10.1021/cr020010d"
    },
    {
      "key": "2022060808370904900_BIB28",
      "doi-asserted-by": "crossref",
      "unstructured": "Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene\u20082003;22:7265\u201379.",
      "DOI": "10.1038/sj.onc.1206933"
    },
    {
      "key": "2022060808370904900_BIB29",
      "doi-asserted-by": "crossref",
      "unstructured": "Niedner H, Christen R, Lin X, Kondo A, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol\u20082001;60:1153\u201360.",
      "DOI": "10.1124/mol.60.6.1153"
    },
    {
      "key": "2022060808370904900_BIB30",
      "doi-asserted-by": "crossref",
      "unstructured": "Bradford CR, Wolf GT, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg\u20081999;121:534\u20138.",
      "DOI": "10.1016/S0194-5998(99)70052-5"
    },
    {
      "key": "2022060808370904900_BIB31",
      "doi-asserted-by": "crossref",
      "unstructured": "Osford SM, Dallman CL, Johnson PW, Ganesan A, Packham G. Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. Curr Med Chem\u20082004;11:1031\u20139.",
      "DOI": "10.2174/0929867043455486"
    },
    {
      "key": "2022060808370904900_BIB32",
      "doi-asserted-by": "crossref",
      "unstructured": "Kitada S, Leone M, Sareth S, et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem\u20082003;46:4259\u201364.",
      "DOI": "10.1021/jm030190z"
    },
    {
      "key": "2022060808370904900_BIB33",
      "doi-asserted-by": "crossref",
      "unstructured": "Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(\u2212)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther\u20082005;4:13\u201321.",
      "DOI": "10.1158/1535-7163.13.4.1"
    },
    {
      "key": "2022060808370904900_BIB34",
      "doi-asserted-by": "crossref",
      "unstructured": "Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol\u20082003;66:93\u2013103.",
      "DOI": "10.1016/S0006-2952(03)00248-X"
    },
    {
      "key": "2022060808370904900_BIB35",
      "doi-asserted-by": "crossref",
      "unstructured": "Oliver CL, Miranda MB, Shangary S, et al. (\u2212)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther\u20082005;4:23\u201331.",
      "DOI": "10.1158/1535-7163.23.4.1"
    },
    {
      "key": "2022060808370904900_BIB36",
      "unstructured": "Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res\u20081994;54:1707\u201314."
    },
    {
      "key": "2022060808370904900_BIB37",
      "doi-asserted-by": "crossref",
      "unstructured": "Coyle T, Levante S, Shetler M, Winfield J. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neurooncol\u20081994;19:25\u201335.",
      "DOI": "10.1007/BF01051046"
    },
    {
      "key": "2022060808370904900_BIB38",
      "doi-asserted-by": "crossref",
      "unstructured": "Ligueros M, Jeoung D, Tang B, et al. Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Br J Cancer\u20081997;76:21\u20138.",
      "DOI": "10.1038/bjc.1997.330"
    },
    {
      "key": "2022060808370904900_BIB39",
      "doi-asserted-by": "crossref",
      "unstructured": "Shidaifat F, Canatan H, Kulp SK, et al. Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor-\u03b2. Cancer Lett\u20081996;107:37\u201344.",
      "DOI": "10.1016/0304-3835(96)04340-6"
    },
    {
      "key": "2022060808370904900_BIB40",
      "unstructured": "Shidaifat F, Canatan H, Kulp SK, et al. Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle. Anticancer Res\u20081997;17:1003\u20139."
    },
    {
      "key": "2022060808370904900_BIB41",
      "doi-asserted-by": "crossref",
      "unstructured": "Wang X, Wang J, Wong SC, et al. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci\u20082000;67:2663\u201371.",
      "DOI": "10.1016/S0024-3205(00)00857-2"
    },
    {
      "key": "2022060808370904900_BIB42",
      "doi-asserted-by": "crossref",
      "unstructured": "Hou DX, Uto T, Tong X, et al. Involvement of reactive oxygen species-independent mitochondrial pathway in gossypol-induced apoptosis. Arch Biochem Biophys\u20082004;428:179\u201387.",
      "DOI": "10.1016/j.abb.2004.06.007"
    },
    {
      "key": "2022060808370904900_BIB43",
      "unstructured": "Benz CC, Keniry MA, Ford JM, et al. Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol\u20081990;37:840\u20137."
    },
    {
      "key": "2022060808370904900_BIB44",
      "unstructured": "Marcucci G, Stock W, Dai G, et al. G3139, a BCL-2 antisense oligo-nucleotide, in AML. Ann Hematol\u20082004;83 Suppl 1:S93\u20134."
    },
    {
      "key": "2022060808370904900_BIB45",
      "doi-asserted-by": "crossref",
      "unstructured": "Marshall J, Chen H, Yang D, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol\u20082004;15:1274\u201383.",
      "DOI": "10.1093/annonc/mdh317"
    },
    {
      "key": "2022060808370904900_BIB46",
      "doi-asserted-by": "crossref",
      "unstructured": "Tolcher AW, Kuhn J, Schwartz G, et al. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res\u20082004;10:5048\u201357.",
      "DOI": "10.1158/1078-0432.CCR-03-0701"
    },
    {
      "key": "2022060808370904900_BIB47",
      "doi-asserted-by": "crossref",
      "unstructured": "van de Donk NW, de Weerdt O, Veth G, et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia\u20082004;18:1078\u201384.",
      "DOI": "10.1038/sj.leu.2403363"
    }
  ],
  "container-title": "Molecular Cancer Therapeutics",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://aacrjournals.org/mct/article-pdf/4/7/1096/1870482/1096-1104.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "syndication"
    },
    {
      "URL": "https://aacrjournals.org/mct/article-pdf/4/7/1096/1870482/1096-1104.pdf",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2022,
        6,
        8
      ]
    ],
    "date-time": "2022-06-08T09:03:24Z",
    "timestamp": 1654679004000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://aacrjournals.org/mct/article/4/7/1096/290665/Reversal-of-cisplatin-resistance-with-a-BH3"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2005,
        7,
        1
      ]
    ]
  },
  "references-count": 47,
  "journal-issue": {
    "issue": "7",
    "published-online": {
      "date-parts": [
        [
          2005,
          7,
          14
        ]
      ]
    },
    "published-print": {
      "date-parts": [
        [
          2005,
          7,
          1
        ]
      ]
    }
  },
  "URL": "http://dx.doi.org/10.1158/1535-7163.MCT-05-0081",
  "relation": {},
  "ISSN": [
    "1535-7163",
    "1538-8514"
  ],
  "subject": [],
  "published": {
    "date-parts": [
      [
        2005,
        7,
        1
      ]
    ]
  }
}